HIV-1 subtype distribution and the problem of drug resistance.
about
Roles and functions of HIV-1 Tat protein in the CNS: an overviewEvolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypesDifferential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CDevelopment of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors.Molecular epidemiology of HIV in two highly endemic areas of northeastern South Africa.Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples.Theme and variations in the evolutionary pathways to virulence of an RNA plant virus species.Transmitted drug resistance in nonsubtype B HIV-1 infection.Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitorsPatterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.A small set of succinct signature patterns distinguishes Chinese and non-Chinese HIV-1 genomes.Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitorsIntra- and intersubtype alternative Pak2-activating structural motifs of human immunodeficiency virus type 1 NefCharacterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load.HIV-1 subtype characteristics of infected persons living in southwestern Greece.Worldwide molecular epidemiology of HIV.Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.HIV clades B and C are associated with reduced brain volumetricsChallenges and Clinical Decision-Making in HIV-to-HIV Transplantation: Insights From the HIV Literature.Proceedings from the NIMH symposium on "NeuroAIDS in Africa: neurological and neuropsychiatric complications of HIV".Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.HIV-1 subtype and reverse transcriptase genotype: role for geographical location and founder effects.Human immunodeficiency virus type-1 subtypes of infected patients in Espírito Santo, Brazil.Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.Impact of genetic variation of HIV-1 on drug resistance developmentHIV subtypes in Scotland, 2000-2006
P2860
Q26996314-DF8071A1-F2E3-444C-AF47-A1F51BBB7C0FQ28473878-640E6012-1D83-482A-AF09-71B92772FF60Q28484213-4E0CCCE9-3D73-480E-8E8B-C92482E65489Q30351993-655ED39A-4851-4FAF-B68B-D950BF23B6E6Q30357556-FD2B5F5C-1E73-4B5B-9B1A-0551C60E6217Q30483107-E68D98EA-4418-4A0D-B2FC-25ADA5FCA690Q33307185-2597B394-F715-4E08-BE51-FECA9BEB6578Q33567164-07416365-1AFC-4ECD-BADA-5FE23D6B5BBFQ33770040-AC848798-0143-4ABD-8ABB-5DE64DE4DCF1Q33964088-FFC4E370-5343-4EAB-9FF7-FDD1977BE62BQ34634310-F1AB9EEB-528D-4B42-BF01-ACA3A7AF633EQ34714684-79E539DA-F4E1-4FD4-84E5-8CBF5BC621BBQ34717615-BE449BEB-0E04-4ED4-AB03-6742D68526E9Q35024084-1D4D1073-3D86-42E6-82B3-41901E93B80FQ36099251-648B81E9-4540-44AD-BF10-F33E03D190A9Q36173963-19EC3C7E-FC04-48A1-BF04-C4CD1FE5D2A3Q36391005-D7D3D060-35F4-48AB-8004-C2A9F6909F65Q36438805-9B51671A-1770-4C1A-BBEE-56C7403E97F0Q36833511-A09525F1-D11F-4E61-80F3-F3D6679F0786Q37354426-8C5623A6-983C-405F-AFA0-907D2616176FQ38529520-E5D5E368-CD8F-461F-B874-ABDAC743E2D7Q38836374-14B872F1-C1D4-4A85-B3BB-4BC4ABE16D3AQ39421000-C6A3F30F-F006-426C-AEAD-55D450DC8569Q41090342-1987D9D6-7953-4CAA-8E0A-67D1132FCC23Q43033164-D2EC2374-3BA5-4436-91D8-6DE54D0CD2D2Q45407359-F456E392-36CB-4A20-9928-3056872D3CBDQ47597201-4DD6A56D-A513-4A74-9B5E-C1BB02117FC1Q56778296-4D39860A-FA66-4E54-951F-BE8688FDB6CEQ56952376-4BFB1829-54B2-4768-B8A7-987220210AA1
P2860
HIV-1 subtype distribution and the problem of drug resistance.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
HIV-1 subtype distribution and the problem of drug resistance.
@ast
HIV-1 subtype distribution and the problem of drug resistance.
@en
type
label
HIV-1 subtype distribution and the problem of drug resistance.
@ast
HIV-1 subtype distribution and the problem of drug resistance.
@en
prefLabel
HIV-1 subtype distribution and the problem of drug resistance.
@ast
HIV-1 subtype distribution and the problem of drug resistance.
@en
P1433
P1476
HIV-1 subtype distribution and the problem of drug resistance.
@en
P2093
Mark A Wainberg
P356
10.1097/00002030-200406003-00012
P407
P478
18 Suppl 3
P577
2004-06-01T00:00:00Z